Unlocking the Biology of RAGE in Diabetic Microvascular Complications

Overview

Journal Trends Endocrinol Metab

Specialty Endocrinology

Date 2013 Sep 10

PMID 24011512

Citations 103

Authors

Michaele B Manigrasso

Judyta Juranek

Ravichandran Ramasamy

Ann Marie Schmidt

Affiliations

Soon will be listed here.

Abstract

The discovery of the receptor for advanced glycation end-products (RAGE) set the stage for the elucidation of important mechanisms underpinning diabetic complications. RAGE transduces the signals of advanced glycation end-products (AGEs), proinflammatory S100/calgranulins, and high mobility group box 1 (HMGB1), and is a one of a family of receptors for lysophosphatidic acid (LPA). These ligand tales weave a theme of vascular perturbation and inflammation linked to the pathogenesis of the chronic complications of diabetes. Once deemed implausible, this concept of inflammatory cues participating in diabetic complications is now supported by a plethora of experimental evidence in the macro- and microvasculature. We review the biology of ligand-RAGE signal transduction and its roles in diabetic microvascular complications, from animal models to human subjects.

Citing Articles

Research progress of gut microbiome and diabetic nephropathy.

Chu C, Behera T, Huang Y, Qiu W, Chen J, Shen Q Front Med (Lausanne). 2024; 11:1490314.

PMID: 39735707 PMC: 11671260. DOI: 10.3389/fmed.2024.1490314.

Role of the receptor for advanced glycation end products in the severity of SARS-CoV-2 infection in diabetic patients.

Pedreanez A, Mosquera-Sulbaran J, Tene D Diabetol Int. 2024; 15(4):732-744.

PMID: 39469543 PMC: 11512988. DOI: 10.1007/s13340-024-00746-1.

Inflammation and aging-related disease: A transdisciplinary inflammaging framework.

Andonian B, Hippensteel J, Abuabara K, Boyle E, Colbert J, Devinney M Geroscience. 2024; 47(1):515-542.

PMID: 39352664 PMC: 11872841. DOI: 10.1007/s11357-024-01364-0.

Role of Receptor for Advanced Glycation End-Products in Endometrial Cancer: A Review.

Zglejc-Waszak K, Jozwik M, Thoene M, Wojtkiewicz J Cancers (Basel). 2024; 16(18).

PMID: 39335163 PMC: 11430655. DOI: 10.3390/cancers16183192.

Glycosylated Hemoglobin (HbA1C) as a Predictor of Early Postoperative Outcomes After Coronary Artery Bypass Grafting: A Single-Center Observational Study.

Alshair F, Baghaffar A, Fatani M, Alqahtani A, Al Assiri A, Alsulymani B Cureus. 2024; 16(7):e65567.

PMID: 39192939 PMC: 11348824. DOI: 10.7759/cureus.65567.

References

Pala L, Cresci B, Manuelli C, Maggi E, Yamaguchi Y, Cappugi P . Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation. Microvasc Res. 2005; 70(3):179-88. DOI: 10.1016/j.mvr.2005.10.001. View

Perkins B, Rabbani N, Weston A, Ficociello L, Adaikalakoteswari A, Niewczas M . Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes. PLoS One. 2012; 7(4):e35655. PMC: 3338454. DOI: 10.1371/journal.pone.0035655. View

Chang K, Liang J, Tsai P, Wu M, Hsu K . Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen. Br J Pharmacol. 2009; 157(8):1419-26. PMC: 2765312. DOI: 10.1111/j.1476-5381.2009.00309.x. View

Singleton J, Smith A . The diabetic neuropathies: practical and rational therapy. Semin Neurol. 2012; 32(3):196-203. DOI: 10.1055/s-0032-1329195. View

Yan S, Yan S, Ramasamy R, Schmidt A . Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med. 2009; 41(6):408-22. PMC: 2932796. DOI: 10.1080/07853890902806576. View

Abbott C, Malik R, van Ross E, Kulkarni J, Boulton A . Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011; 34(10):2220-4. PMC: 3177727. DOI: 10.2337/dc11-1108. View

Hirai F, Tielsch J, Klein B, Klein R . Ten-year change in vision-related quality of life in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology. 2010; 118(2):353-8. PMC: 3017211. DOI: 10.1016/j.ophtha.2010.06.022. View

Arumugam T, Simeone D, Schmidt A, Logsdon C . S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem. 2003; 279(7):5059-65. DOI: 10.1074/jbc.M310124200. View

Han Y, Randell E, Vasdev S, Gill V, Curran M, Newhook L . Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with Type 1 diabetes. Clin Biochem. 2009; 42(7-8):562-9. DOI: 10.1016/j.clinbiochem.2008.12.016. View

10.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

11.

Bolton W, Cattran D, Williams M, Adler S, Appel G, Cartwright K . Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol. 2003; 24(1):32-40. DOI: 10.1159/000075627. View

12.

Shibasaki M, Sasaki M, Miura M, Mizukoshi K, Ueno H, Hashimoto S . Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury. Pain. 2010; 149(3):514-521. DOI: 10.1016/j.pain.2010.03.023. View

13.

Mohammad G, Siddiquei M, Othman A, Al-Shabrawey M, Abu El-Asrar A . High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Exp Eye Res. 2012; 107:101-9. DOI: 10.1016/j.exer.2012.12.009. View

14.

Monnier V, Sell D, Strauch C, Sun W, Lachin J, Cleary P . The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. J Diabetes Complications. 2012; 27(2):141-9. PMC: 3577949. DOI: 10.1016/j.jdiacomp.2012.10.004. View

15.

Kaida Y, Fukami K, Matsui T, Higashimoto Y, Nishino Y, Obara N . DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes. 2013; 62(9):3241-50. PMC: 3749365. DOI: 10.2337/db12-1608. View

16.

Roy M, Klein R, OColmain B, Klein B, Moss S, Kempen J . The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol. 2004; 122(4):546-51. DOI: 10.1001/archopht.122.4.546. View

17.

Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K . Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes. 1992; 41(1):47-52. DOI: 10.2337/diab.41.1.47. View

18.

Aranda J, Motiejunaite R, Im E, Kazlauskas A . Diabetes disrupts the response of retinal endothelial cells to the angiomodulator lysophosphatidic acid. Diabetes. 2012; 61(5):1225-33. PMC: 3331768. DOI: 10.2337/db11-1189. View

19.

El-Mesallamy H, Hamdy N, Ezzat O, Reda A . Levels of soluble advanced glycation end product-receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot. J Investig Med. 2011; 59(8):1233-8. DOI: 10.2130/JIM.0b013e318231db64. View

20.

Schleicher E, Wagner E, Nerlich A . Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997; 99(3):457-68. PMC: 507819. DOI: 10.1172/JCI119180. View